Significant Progress in New Genomic Techniques Legislation
In a momentous development for Cibus, Inc. and the agricultural sector, the company has expressed enthusiasm over the fruitful completion of trilogue negotiations regarding New Genomic Techniques (NGTs) in the European Union (EU). This agreement is pivotal as it lays down the foundation for a modern framework that supports the innovative gene editing required for advancing plant breeding.
A Framework for Innovation
The recent agreement reached by the European Parliament and Council aims to provide a clear regulatory pathway for gene-edited plants, also known as NGTs. This new legislative framework is crucial as it signifies a shift towards embracing technologies that can enhance agricultural productivity and sustainability, giving European growers access to improved plant varieties.
A Call to Action from the Industry
The negotiations were spurred by an urgent call for action from various European agri-food organizations, emphasizing the need for supportive policies related to gene editing. The newly established regulations enable the development and cultivation of gene-edited plants, reflecting the European Commission's original proposal.
Cibus' Commitment to Innovative Solutions
Peter Beetham, PhD, Co-Founder and Interim CEO of Cibus, articulated the company's commitment, stating, "This agreement solidifies the European Union’s commitment to embracing gene editing technology and opens the door for the development of improved plant varieties for the European market." Cibus primarily focuses on developing high-value traits aimed at enhancing productivity for European farmers.
Leadership in Legislative Negotiations
The successful outcome of the trilogue negotiations highlights the dedicated efforts of the Danish Council Presidency and the lead rapporteur from the European Parliament, Jessica Polfjärd. Their leadership and commitment were instrumental in driving the negotiations to a successful conclusion.
Field Trials Propel Cibus Forward
As the EU moves towards implementing its NGT regulatory framework, Cibus has proactively conducted field trials in the UK. One notable achievement is their progress in developing a trait that reduces pod shattering in winter oilseed rape, demonstrating their readiness to meet future regulatory demands.
Future Opportunities in the European Market
Tony Moran, Senior Vice President of International Development and Government Affairs, emphasized, "This pivotal moment justifies our focus on the UK as we work to develop traits for the European market." This strategic pivot provides Cibus a competitive edge in nurturing valuable agricultural solutions tailored to the evolving landscape.
Addressing Agricultural Challenges
The new legislative developments not only provide clarity but also enhance Cibus' pipeline of innovative products designed to tackle pressing agricultural challenges. With a commitment to addressing issues like disease resistance and optimizing nitrogen use efficiency, Cibus is dedicated to giving farmers effective tools to improve on-farm productivity.
About Cibus
Cibus is at the forefront of gene editing technology aimed at creating productivity-enhancing traits for farmers. By addressing critical issues such as diseases and pests, which significantly impact the agricultural sector, Cibus aims to revolutionize farming practices. Unlike typical seed companies, Cibus focuses on developing proprietary gene-editing technologies that facilitate faster and more cost-effective advancements in plant traits.
Frequently Asked Questions
What is the significance of the new NGT legislation in the EU?
The new NGT legislation establishes a regulatory framework that supports the development and use of gene-edited plants, promoting innovation in agricultural practices.
How does Cibus contribute to agricultural innovation?
Cibus develops advanced traits through gene editing, which enhances crop productivity, disease resistance, and sustainability for farmers across various markets.
What are gene-edited plants?
Gene-edited plants are those that have undergone modifications to their genetic material using techniques like CRISPR, aimed at improving their characteristics and resistance to stress.
What opportunities does the new framework provide for Cibus?
The regulatory clarity allows Cibus to accelerate its product development efforts and expand its market offerings in Europe, meeting the needs of modern agricultural practices.
Who can I contact for more information about Cibus?
For inquiries, please reach out to Jeff Sonnek in Investor Relations at jeff.sonnek@icrinc.com or Colin Sanford in Media Relations at colin@bioscribe.com.
